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Abstract
Both metabolic syndrome (MetS) and elevated LDL cholesterol (LDL-C) increase the risk for cardiovascular disease (CVD). We hypothesized 
that low HDL cholesterol (HDL-C) would further increase CVD risk in women having both conditions.  To assess this, we recruited 89 women
with MetS (25-72 y) and LDL-C ≥2.6 mmol/L. To determine whether plasma HDL-C concentrations were associated with dietary components,
circulating atherogenic particles, and other risk factors for CVD, we divided the subjects into two groups: high HDL-C (H-HDL) (≥1.3 mmol/L,
n = 32) and low HDL-C (L-HDL) (< 1.3 mmol/L, n = 57). Plasma lipids, insulin, adiponectin, apolipoproteins, oxidized LDL, Lipoprotein(a), and 
lipoprotein size and subfractions were measured, and 3-d dietary records were used to assess macronutrient intake. Women with L-HDL had higher
sugar intake and glycemic load (P< 0.05), higher plasma insulin (P< 0.01), lower adiponectin (P< 0.05), and higher numbers of atherogenic lipoproteins
such as large VLDL (P< 0.01) and small LDL (P< 0.001) than the H-HDL group. Women with L-HDL also had larger VLDL and both smaller
LDL and HDL particle diameters (P< 0.001). HDL-C was positively correlated with LDL size (r = 0.691, P< 0.0001) and HDL size (r = 0.606,
P< 0.001), and inversely correlated with VLDL size (r = -0.327, P < 0.01). We concluded that L-HDL could be used as a marker for increased 
numbers of circulating atherogenic lipoproteins as well as increased insulin resistance in women who are already at risk for CVD. 
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Introduction7)
The metabolic syndrome (MetS) is a constellation of metabolic 
abnormalities characterized by abdominal obesity, hyperglycemia, 
high blood pressure, and dyslipidemias including elevated 
apolipoprotein B (apo-B), high plasma triglycerides (TG), increased 
numbers of small, dense LDL particles, and low HDL-cholesterol 
(HDL-C) concentrations [1]. The cluster of these characteristics 
poses individuals at higher risk for both cardiovascular disease 
(CVD) and type 2 diabetes [2].
The inverse association between low plasma concentrations of 
HDL-C and atherosclerosis has been clearly established [3]. The 
protective effects of HDL against CVD risk are not limited to 
the role of this lipoprotein in reverse cholesterol transport [4]. 
HDL has a number of pleiotropic functions, including the 
transport of paraoxonase 1, an important anti-oxidant in plasma 
[5], as well as the promotion of cholesterol removal from 
macrophages [6], regulation of endothelial adhesion molecule 
expression [7], anti-inflammatory effects [8], and nitric oxide 
promoting action [9]. What is clear from previous studies [4-9] 
is that elevated concentrations of HDL-C are protective against 
CVD and atherosclerosis through many different mechanisms. 
This protective role of HDL may also be extended to subjects 
who present other risk factors for heart disease. 
Dietary carbohydrate has been shown to modulate the risk 
factors associated with MetS [10]. For example, carbohydrate- 
restricted diets decrease plasma TG [11], elevate HDL-C [12], 
and reduce the number of circulating small LDL [13]. Since fat 
accumulation in the trunk area has been shown to be associated 
with increased free fatty acid release, insulin resistance, and 
disruption of glucose metabolism [10], reductions of fat in this 
area are quite beneficial to reduce the risk of CVD and type 
2 diabetes [2]. The primary aim of the present study was to 
investigate whether low concentrations of HDL-C would result 
in increased numbers of atherogenic lipoproteins and insulin 
resistance in women already at risk for CVD. Based on this, 
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we evaluated several risk parameters for CVD and atherosclerosis 
in women having high (H-HDL) (> 1.3 mmol/L) versus low 
(L-HDL) (< 1.3 mmol/L) plasma HDL-C concentrations. These 
subjects had high LDL-C (> 2.6 mmol/L) and were also classified 
as having MetS, two conditions that increase CVD risk. A 
secondary objective was to determine whether dietary components 
were related to low concentrations of HDL-C. 
Subjects and Methods
Study design 
The subjects for this study were recruited from 3 different 
locations: the University of Connecticut (Storrs, CT) (n = 29), 
University of Florida (Jacksonville, FL) (n = 47), and University 
of California (Irvine, CA) (n = 13). The inclusion criteria were 
women with MetS, having at least 2 of the following 
characteristics: blood pressure ≥130/85 mm Hg or treated 
hypertension, waist circumference (WC) > 88 cm, fasting glucose 
≥5.6 mmol/L, and HDL-C < 1.3 mmol/L, in addition to high 
TG (≥1.7 mmol/L) and LDL-C ≥2.6 mmol/L.
The subjects were recruited by word of mouth, distribution 
e-mails, newspaper and radio advertisements, and flyers. The 
exclusion criteria were low LDL-C (< 2.6 mmol/L), TG < 1.7 
mmol/L, age less than 25 or older than 75 y, pregnancy, lactation, 
thyroid problems, stroke, heart disease, or use of medication or 
supplements relevant to diabetes or CVD such as hypoglycemic 
or cholesterol lowering agents. A total of 89 women were 
recruited for the study. All protocols were approved by the 
Institutional Review Boards of the respective universities. 
Anthropometrics and blood pressure
After obtaining a consent agreement from each participant, 
weight and height were measured and body mass index (BMI) 
was calculated (kg/m
2). WC was calculated by measuring at the 
superior border of the iliac crest using a flexible tape. Blood 
pressure (systolic and phase-V diastolic) was measured on the 
left
  arm with the subjects seated, after at least 5 minutes rest, 
using an automated blood pressure monitor (Omron, Healthcare 
Inc., Bannockburn, IL). Three separate recordings were made and 
the mean was used. 
Diet analysis 
The subjects completed a 3-d diet record including one 
week-end day to assess energy, carbohydrate, fat, protein, dietary 
fiber, and cholesterol intake as well as glycemic load, which was 
automatically calculated. The dietary records were analyzed using 
The Nutrition Data System 9.0 (Minneapolis, MN). 
Laboratory measurements
After a 12-h overnight fast, 60 ml of fasting blood was 
collected from all participants. Plasma was separated from red 
blood cells by centrifugation at 2000 × g, aliquoted, and then 
frozen at -80℃  for further analysis. Plasma lipids, glucose, 
insulin, apo B, and apo A-I were measured in a certified 
laboratory (Northwest Lipid Research Laboratories, Seattle, WA). 
Plasma glucose and lipids were assayed using a Vitros 950IRC 
analyzer (Ortho-Clinical Diagnostics, Rochester, NY). LDL-C 
was determined indirectly using the Friedewald equation [14]. 
Apo A-I and B were analyzed by turbidimetry using an Advia 
1650
® (Bayer Diagnostics, Tarrytown, NY). Insulin was 
determined by a chemiluminescent, immunometric assay using 
a DPC Immulite 2000 (Diagnostics Products Corporation, Nutley, 
NJ). The homeostasis model assessment (HOMA) [15] was 
calculated as a measure of insulin resistance.
Lipoprotein subfractions and size
H-NMR analysis was performed (LipoScience, Inc., Raleigh, 
NC) using a 400 MHz NMR analyzer (Bruker BioSpin Corp, 
Billerica, MA) as previously described [13]. NMR simultaneously 
quantifies > 30 lipoprotein subclasses that are empirically 
grouped into 9 smaller subclasses based on the following particle 
diameters: large VLDL (35-60 nm), medium VLDL (27-35 nm), 
small VLDL (23-27 nm), large LDL (21.2-23 nm), medium LDL 
(19.8-21.2 nm), small LDL (18-19.8 nm), large HDL (8.8-13 nm), 
medium HDL (8.2-8.8 nm), and small HDL (7.3-8.2 nm). 
Weighted-average lipoprotein particle sizes in diameter were 
calculated based on the diameter of each lipoprotein subclass 
multiplied by its respective relative concentration.
Apolipoproteins A-II, C-II, C-III, and E
Apolipoproteins were measured using LINCOplex: Multiplex 
Biomarker Immunoassay for Luminex Instrumentation/xMAP 
Technology (Austin, TX). This technique uses fluorescently 
labeled microsphere beads with antibodies specific to each 
individual apolipoprotein [16]. The technique is well standardized 
in our laboratory [11].
LDL oxidation and Lipoprotein(a)
LDL oxidation was measured by ELISA kits (ALPCO, Salem, 
NH) using the monoclonal antibody 4E6, which has been utilized 
in numerous clinical trials [17]. The standards and samples were 
read at 450 nm in a spectrophotometer (Spectramax Multimode 
Spectrophotometer, Sunnyvale, CA). Using a polynomial curve, 
concentrations of oxidized LDL were calculated and expressed 
as mmol/L. Plasma Lp(a) was determined in duplicate using a 
sandwich ELISA (Diagnostic Automation, Inc., Calabasas, CA) 
with a dynamic range of 0.04-5.89 µmol/L. Absorbance was 494 Low HDL in the metabolic syndrome
Fig. 1. Percent of subjects with waist circumference (WC) > 88 cm, blood 
pressure > 130/85 mm Hg; plasma glucose > 100 mg/dL (5.6 mmol/L); plasma 
triglycerides (TG) > 150 mg/dL (1.7 mmol/L) and HDL < 50 mg/dL (1.3 mmol/L) 
in women classified with metabolic syndrome (MetS) (n = 89)
Parameter High HDL-C (n = 32) Low HDL-C (n = 57)
Age (yr) 47.6 ± 9.8 46.6 ± 10.7
Weight (kg) 93.0 ± 17.0 90.3 ± 13.1
BMI (kg/m2) 34.2 ± 5.7 34.0 ± 5.0
WC (cm) 110.7 ± 11.9 107.6 ± 10.5
Systolic (mm Hg) 127.8 ± 13.3 126.8 ± 15.9
Diastolic (mm Hg) 81.0 ± 7.7 78.8 ± 8.9
TC (mmol/L) 5.96 ± 0.80 5.66 ± 0.85
LDL-C (mmol/L) 3.50 ± 0.85 3.56 ± 0.72
HDL-C (mmol/L) 1.48 ± 0.16 1.03 ± 0.16**
TG (mmol/L) 2.17 ± 0.38 2.37 ± 0.67
Glucose (mmol/l) 4.86 ± 0.70  4.97 ± 0.80
Insulin (µU/mL) 13.2 ± 6.2 18.8 ± 9.9*
Insulin resistance (HOMA) 3.2 ± 1.6 4.5 ± 2.8*
Adiponectin (mg/L) 16.4 ± 6.8 13.8 ± 7.4*
ICAM (mg/L) 0.094 ± 0.027 0.17 ± 0.049*
Apo B (mg/L)  1,115.3 ± 210.8 1,216.0 ± 217.4
Apo A-I (mg/L)  1711 ± 250 1415 ± 161**
Apo A-II (mg/L)  225.5 ± 83.8 168.5 ± 51.7**
Apo C-II (mg/L)  100.9 ± 34.1 87.0 ± 38.7*
Apo C-III (mg/L)  284.6 ± 99.3 252.9 ± 119.5*
Apo E (mg/L)  75.9 ± 37.2 71.5 ± 28.3
1) Values  are  mean ± SD  for  the  number  of  subjects  indicated  in  parentheses. 
* Significantly different at P<0.05, ** Significantly different at P<0.001 as determined 
by  Mann-Whitney  U  non-parametric  test
Table 1. Anthropometrics, blood pressure, plasma lipids, glucose, insulin and 
apolipoproteins (apo) of women classified with MetS having low (< 1.3 mmol/L)
or high (≥1.3 mmol/L) HDL-C
1)
Parameter High HDL-C (n = 32) Low HDL-C (n = 57)
Total energy (Kjoules/d) 8,622 ± 3,349 8,921 ± 3,374
Total fat (g/d) 101.8 ± 55.0 92.6 ± 46.9
Total fat (% energy) 38.5 ± 7.4 36.5 ± 7.7
Saturated fat (% energy) 13.5 ± 3.5 12.0 ± 3.2*
Monounsaturated fat 
(% energy)
14.8 ± 4.5 13.6 ± 3.1
Polyunsaturated fat 
(% energy)
9.5 ± 8.3 7.9 ± 3.2
Trans fatty acids (g/d) 4.4 ± 2.9 5.4 ± 3.5
Omega-3 fatty acids (g/d) 1.9 ± 1.2 1.9 ± 1.1
Total carbohydrate (g/d) 211.5 ± 101.3 234.2 ± 86.4
Carbohydrate (% energy) 42.2 ± 8.1 44.7 ± 10.0
Total sugars(g/d) 76.4 ± 48.9 103.1 ± 58.9*
Added sugars (g/d) 48.5 ± 42.0 76.4 ± 56.2*
Glycemic Load 116.4 ± 60.4 133.3 ± 53.2*
Total protein (g/d) 79.7 ± 41.7 86.1 ± 29.6
Protein (% energy) 15.9 ± 4.0 17.0 ± 4.4
Dietary cholesterol (mg/d) 321.2 ± 168.9 331.0 ± 173. 
Alcohol (% energy) 3.2 ± 5.2 2.4 ± 5.8*
Total fiber (g/d) 18.3 ± 10.8 16.4 ± 8.1
Soluble fiber (g/d) 5.6 ± 3.1 5.3 ± 2.5
Insoluble fiber (g/d) 12.5 ± 8.3 10.9 ± 6.4
1) Values  are  mean ± SD. 
* Indicates  significantly  different  (P < 0.05)  as  determined  by  Mann-Whitney  non- 
parametric  test 
Table 2. Total Energy, fat, carbohydrate, protein, dietary cholesterol and dietary
fiber intake obtained from a 3-d dietary record of women classified with MetS
having low (< 1.3 mmol/L) or high (≥1.3 mmol/L) HDL-C
1)
determined using the same spectrophotometer as previously 
reported [18].
Adiponectin and intercellular adhesion molecule-1 (sICAM-1) 
From fasting plasma, ICAM-1 and adiponectin were measured 
in duplicate in the same assay using Human CVD Panel 1 
LINCOplex kits. Samples were diluted 1:100 and simultaneously 
quantified by using Antibody-Immobilized Beads and Luminex 
xMAP technology. All assays were carried out on the same day 
to decrease variability. The coefficient variation was 2-6%. The 
sensitivities for sICAM-1 and adiponectin were 9.0 pg/ml and 
56.0 pg/ml, respectively, as previously reported [19].
Statistical analysis
Data are presented as mean ± SD for the measured parameters. 
Since we had different numbers of subjects in the low and high 
HDL-C groups, the non-parametric Mann-Whitney U test was 
performed to assess differences in plasma lipids, apolipoproteins, 
diet, inflammatory markers, and lipoprotein size and subfractions. 
P < 0.05 was considered significant. Pearson correlations were 
conducted between HDL-C and the different lipoprotein sizes.
Results
All 89 women recruited for the study were classified as having 
MetS. All women (100%) had high TG (≥1.7 mmol/L), as this 
was one of the inclusion criteria, and 99% had WC > 88 cm. 
Fasting blood glucose > 5.6 mmol/L, high blood pressure (≥
130/85 mm Hg), and low HDL-C (< 1.3 mmol/L) accounted for 
39, 47, and 64% of the subjects, respectively (Fig. 1).
We divided the women into two groups according to the 
following concentrations of plasma HDL-C: H-HDL ≥ 1.3 
mmol/L and L-HDL < 1.3 mmol/L, to evaluate whether lower 
HDL-C would be associated with higher risk for atherosclerosis. Maria Luz Fernandez et al. 495
A
B
C
Fig. 2. Correlations between HDL-C and VLDL size (panel A) HDL size (panel 
B) and LDL size (panel C)
Parameter High HDL-C (n = 32) Low HDL-C (n = 57)
VLDL diameter (nm) 51.1 ± 7.0 54.7 ± 8.1*
Total VLDL (mmol/L) 97 ± 33 104 ± 39
Large VLDL (mmol/L) 4.8 ± 3.1 8.4 ± 7.8*
Medium VLDL (mmol/L) 35.9 ± 17.5 41.6 ± 24.6
Small VLDL (mmol/L) 56.5 ± 18.6 53.6 ± 20.7
IDL (mmol/L) 65.4 ± 53.1 87.1 ± 49.7*
LDL diameter (nm) 21.0 ± 0.6 20.2 ± 0.6*
Total LDL (mmol/L) 1490 ± 366 1734 ± 345*
Large LDL (mmol/L) 513 ± 158 288 ± 169*
Small LDL (mmol/L) 932 ± 388 1,359 ± 384*
HDL diameter (nm) 8.9 ± 0.3 8.6 ± 0.2*
Total HDL (mmol/L) 39.5 ± 6.2 33.6 ± 4.9*
Large HDL (mmol/L) 8.3 ± 3.5 4.2 ± 2.4*
Medium HDL (mmol/L) 6.9 ± 5.6 6.3 ± 4.6
Small HDL (mmol/L) 24.3 ± 6.9 23.1 ± 5.3
Oxidized LDL (µg/L)  112.1 ± 94.8 118.6 ± 98.7
Lp(a) (µmol/L)  0.92 ± 0.81 0.69 ± 0.72
1) Values are mean±SD. Values in a row with different superscripts are significantly 
different  (P < 0.01)  as  determined  by  Mann-Whitney  non-parametric  test
Table 3. Number of VLDL, IDL, LDL and HDL particles according to size, 
apolipoproteins, VLDL, LDL and HDL diameters, LDL oxidation and Lp(a) of 
women classified with MetS having low (< 1.3 mmol/L) or high (≥1.3 mmol/L) 
HDL-C
1)
As indicated in Table 1, age, BMI, WC, weight, and systolic 
and diastolic blood pressure were not different between groups. 
Likewise, the risk factors of total cholesterol, LDL-C, apo B, 
apo E, and glucose were not different between the high and low 
HDL groups. However, HDL-C (by definition), apo A-I, apo 
A-II, apo C-II, and apo C-III were higher in the H-HDL group. 
Insulin, HOMA, adiponectin, and ICAM were lower (P< 0.0001) 
in the H-HDL group (Table 1).
Regarding dietary intake, women from the H-HDL group 
consumed more saturated fat, as well as energy from alcohol 
(P< 0.05), while they consumed less sugar and added sugar than 
subjects in the L-HDL group (Table 2). Other dietary components 
including total fat, protein, dietary cholesterol, fiber, and different 
types of fatty acids were not different between groups. Positive 
correlations were found between HDL-C and LDL size (r =
0.628,  P < 0.0001) and HDL size (r = 0.606, P < 0.0001), and 
a negative correlation was found between HDL-C and VLDL 
size (r = -0.327, P < 0.01) (Fig. 2). 
Concentrations of lipoprotein subclasses, lipoprotein size, 
oxidized LDL, and Lp(a), which are major biomarkers of 
atherosclerosis risk, were also evaluated in women with high or 
low concentrations of HDL-C (Table 3). The H-HDL group 
presented a less atherogenic lipoprotein profile with lower 
concentrations of large VLDL, small LDL, and IDL compared 
to the L-HDL group. Furthermore, lipoprotein size was modified 
by the concentration of HDL-C in plasma. Women with L-HDL 
had lower numbers of large LDL (P < 0.0001), and therefore a 
smaller LDL diameter (P < 0.01) than those from the H-HDL 
group. The L-HDL group also had larger VLDL (P<0 . 0 5 )  a n d  
smaller HDL (P< 0.05) diameters than the H-HDL group (Table 
3). Concentrations of oxidized LDL and Lp(a) had a wide range 
among participants; however, they were not different between 
HDL groups (Table 3). 
Discussion
In this study we evaluated the adverse effects of HDL-C in 
concentrations of less than 1.3 mmol/L in women with high risk 
for CVD, mainly a population classified with MetS and the 
additional risk factor of plasma LDL-C ≥2.6 mmol/L. Our data 
analysis suggests that HDL-C < 1.3 mmol/L further increases the 
risk of CVD and atherosclerosis. The novel aspect of this study 
is that L-HDL appears to be a biomarker of elevated 
concentrations of circulating atherogenic lipoproteins as well as 
increased insulin resistance and lower concentrations of 496 Low HDL in the metabolic syndrome
adiponectin, all of which are key biomarkers of increased risk 
for type 2 diabetes and coronary heart disease. Although 
participants in this study had dietary habits that might increase 
risk for heart disease such as a high intake of trans fatty acids 
and low intakes of omega-3 fatty acids and dietary fiber, high 
simple sugar intake and high glycemic load were the dietary 
components that might have been correlated with low 
concentrations of HDL-C.
A main concern regarding MetS is the predisposition to glucose 
intolerance, insulin resistance, and diabetes [2]. The consumption 
of foods with a low glycemic index has been advocated for 
amelioration of dysfunctional glucose metabolism for more than 
two decades [20]. Diets based on varying degrees of carbohydrate 
restriction also have demonstrated efficacy in improving glucose 
metabolism and associated metabolic aberrations [10]. In the 
present, study, the women with lower HDL-C (< 1.3 mmol/L) 
consumed more sugar and had higher glycemic loads than those 
from the H-HDL group. Interestingly, women from the L-HDL 
groups also consumed less alcohol and less saturated fat. 
Moderate increases in alcohol have been correlated with higher 
HDL-C and paraoxanase-1, suggesting a protective effect against 
CVD [21], and all fatty acids including saturated fatty acids (with 
the exception of trans fat) have been correlated with increased 
HDL-C [22]. Thus, the above results are not surprising.
The women with L-HDL also had higher concentrations of 
plasma insulin and greater insulin resistance as determined by 
HOMA, along with lower concentrations of adiponectin. In 
agreement with our results, low adiponectin concentrations are 
strongly correlated with insulin resistance [23]. Data from 
epidemiological studies also indicate that circulating adiponectin 
is reduced in patients with CVD and diabetes [24]. To further 
support our findings that HDL-C concentrations predict insulin 
resistance, in a recent study, TG/HDL-C was used as a marker 
of insulin resistance in obese patients [25]. In the present study, 
plasma TG levels did not differ between groups and subjects 
from the H-HDL group had higher apo C-III than those from 
the L-HDL group. These findings suggest that the higher levels 
of apo C-III in the H-HDL group were related to the increased 
number of HDL particles available to transport this 
apolipoprotein. While apo C-III present in VLDL is associated 
with decreased lipoprotein lipase activity, apo C-III transported 
by HDL indicates a reservoir of this apolipoprotein [26]. Overall, 
subjects from the L-HDL group appear to be at greater risk for 
the development of diabetes as documented by more elevated 
insulin resistance and lower levels of adiponectin.
Subjects with L-HDL presented increased concentrations of the 
atherogenic lipoproteins large VLDL, small LDL, and IDL. 
Furthermore, these women had lower concentrations of the larger, 
more buoyant LDL that is considered less atherogenic [27]. In 
addition, impaired endothelial function can be assessed by 
measuring the level of molecules secreted by the endothelium, 
such as sICAM1 [28]. Subjects with L-HDL had increased 
concentrations of this adhesive molecule, which poses at higher 
risk for CVD.
Abnormalities in VLDL particle size seem to be a major 
contributing factor to dysfunctional lipoprotein metabolism [29]. 
Large VLDL particles are classified as atherogenic for two main 
reasons: their ability to interact with macrophages in the arterial 
wall [30] and their easy conversion to small LDL [31]. In addition 
to transporting high concentrations of plasma TG, large VLDL 
also carry high concentrations of cholesterol (5 times more than 
an LDL particle) [30]. These large VLDL are taken up by 
macrophages through cell surface membrane-binding proteins 
leading to the formation of foam cells and the initiation of 
atherosclerosis. In addition, through the delipidation cascade, 
TG-rich VLDL are precursors for the formation of small, dense 
LDL particles and increased HDL catabolism [32]. The 
phenotype characterized by a predominance of small LDL 
particles has been termed pattern B and is typical of MetS and 
diabetes [27]. Small, dense LDL particles are considered more 
atherogenic due to their decreased binding to the LDL receptor, 
leading to increased plasma residence time and an increased 
susceptibility to oxidation [33]. In addition, increased levels of 
small LDL in plasma are associated with increased risk of 
coronary heart disease [33]. IDL, also known as VLDL remnants, 
are part of TG-rich lipoproteins and are associated with increased 
risk for heart disease [34]. All of these atherogenic lipoproteins 
were higher in women with lower concentrations of HDL-C. 
Another observation was that the groups of women with HDL-C 
> 1.3 mmol/L had lower numbers of both total HDL and large 
HDL particles. Since the main function of HDL is to remove 
cholesterol and oxysterols from extra-hepatic cells including 
smooth muscle cells, endothelial cells, and macrophages through 
ABCA1 and ABCG1 transporters [35], a higher number of 
particles suggest a more efficient reverse cholesterol transport 
and increased protection against atherosclerosis.
Both Lp(a) levels and oxidized LDL concentrations did not 
differ between HDL groups. Plasma Lp(a) concentrations are 
reported to have a strong ethnic influence and is correlated with 
increased risk for heart disease both through its atherogenic and 
prothrombotic properties [36]. Specifically, concentrations >
0.71-1.07 µmol/L are associated with 1.5- to 3-fold increases 
of coronary atherosclerosis independent of plasma levels of other 
lipoproteins [36]. In the current study with women at high risk 
for CVD, levels of Lp(a) varied between 0.21 and 4.14 µmol/L. 
Low HDL-C was not associated with higher concentrations of 
Lp(a) in this group of women. Oxidized LDL has been correlated 
with atherosclerosis, diabetes, and renal disease [37]. Small 
significant amounts of oxidized LDL have been detected in 
plasma by use of monoclonal antibodies specific to epitopes of 
oxidized apo B [17]. Among these, 4E6 recognizes MDA 
modified lysine epitopes and has been extensively used in human 
studies [17]. Similar to our findings for Lp(a), the women in 
the current study presented a wide range of oxidized LDL, from 
1.4 to 445 μgl/L. In this group of women, concentrations of both 
biomarkers, Lp(a) and oxidized LDL, for increased risk of CVD, Maria Luz Fernandez et al. 497
were independent of HDL-C concentrations.
The data from this study suggest that low plasma HDL-C (<
1.3 mmol/L) is associated with increased risk of CVD and 
diabetes in women already at risk, and appears to be a biomarker 
of a greater atherogenic lipoprotein profile (decreased large 
VLDL and small LDL). In addition, low concentrations of 
HDL-C are related to a lower number of HDL particles, decreased 
HDL size, and decreased large HDL, conditions that suggest the 
existence of a less efficient reverse cholesterol transport. Finally, 
individuals with low concentrations of HDL-C were at increased 
risk for diabetes, as they presented increased insulin resistance 
and lower concentrations of adiponectin. 
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